A Phase 1 Study Assessing Safety, Tolerability, Pharmacokinetics and Physiological Response (Pain Tolerance) to Single and Multiple Ascending Doses of FZ008-145 in Healthy Subjects.
Latest Information Update: 01 Jun 2026
At a glance
- Drugs FZ 008 (Primary) ; FZ 008 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Guangzhou Fermion Technology
Most Recent Events
- 27 May 2026 Status changed from recruiting to completed.
- 12 Feb 2026 Planned number of patients changed from 168 to 190.
- 12 Feb 2026 Planned End Date changed from 26 Dec 2025 to 1 Jun 2026.